Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (551-560 of 602) with videos related to

Pageof 61
Sort By:
Blood Cancer Journal|March 5, 2021
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patientsPatrick W Mellors, Surendra Dasari, Mindy C Kohlhagen, et al.
Blood Advances|June 29, 2019
Impact of acquired del(17p) in multiple myelomaArjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
American Journal of Hematology|June 4, 2026
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell LeukemiaDaniel G Packard, Shaji K Kumar, Angela Dispenzieri, et al.
The Lancet. Oncology|April 4, 2017
Role of <sup>18</sup>F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working GroupMichele Cavo, Evangelos Terpos, Cristina Nanni, et al.
Blood Cancer Journal|April 19, 2025
Risk of lymphoid malignancy associated with cancer predisposition genesNicholas J Boddicker, Raphael Mwangi, Dennis P Robinson, et al.
Blood Cancer Journal|March 9, 2019
Natural history of multiple myeloma with de novo del(17p)Arjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Blood Advances|January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Blood Cancer Journal|February 1, 2022
A simple additive staging system for newly diagnosed multiple myelomaNadine H Abdallah, Moritz Binder, S Vincent Rajkumar, et al.
Pageof 61

Showing results (551-560 of 602) with videos related to

Sort By:
Pageof 61
Blood Cancer Journal|March 5, 2021
MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patientsPatrick W Mellors, Surendra Dasari, Mindy C Kohlhagen, et al.
Blood Advances|June 29, 2019
Impact of acquired del(17p) in multiple myelomaArjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
American Journal of Hematology|June 4, 2026
Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell LeukemiaDaniel G Packard, Shaji K Kumar, Angela Dispenzieri, et al.
The Lancet. Oncology|April 4, 2017
Role of <sup>18</sup>F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working GroupMichele Cavo, Evangelos Terpos, Cristina Nanni, et al.
Blood Cancer Journal|April 19, 2025
Risk of lymphoid malignancy associated with cancer predisposition genesNicholas J Boddicker, Raphael Mwangi, Dennis P Robinson, et al.
Blood Cancer Journal|March 9, 2019
Natural history of multiple myeloma with de novo del(17p)Arjun Lakshman, Utkarsh Painuly, S Vincent Rajkumar, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Blood Advances|January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Blood Cancer Journal|February 1, 2022
A simple additive staging system for newly diagnosed multiple myelomaNadine H Abdallah, Moritz Binder, S Vincent Rajkumar, et al.
Pageof 61